Cholesterol News and Research

RSS

Cholesterol is a waxy, fat-like substance made in the liver, and found in the blood and in all cells of the body. Cholesterol is important for good health and is needed for making cell walls, tissues, hormones, vitamin D, and bile acid.

Statin drugs can neutralise heart disease dangers of fatty food: Study

Fast food outlets could provide statin drugs free of charge so that customers can neutralise the heart disease dangers of fatty food, researchers at Imperial College London suggest in a new study published this week.Statins reduce the amount of unhealthy "LDL" cholesterol in the blood. A wealth of trial data has proven them to be highly effective at lowering a person's heart attack risk.

13 Aug 2010

FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients

LifeCycle Pharma A/S today announced receipt of agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment of its pivotal Phase 3 study, Study 3002, for LCP-Tacro in patients, who have just received a kidney transplant.

12 Aug 2010

Fast food outlets can provide statin drugs to help customers neutralise heart disease: Researchers

12 Aug 2010

25% of stroke patients stop taking prevention medication within 3 months

At least a quarter of patients who have suffered a stroke stop taking one or more of their prescribed stroke prevention medications within the first three months after being hospitalized - when the chance of having another stroke is highest - according to a new study by researchers at Wake Forest University Baptist Medical Center and colleagues.

12 Aug 2010

Modifiable factors associated with stroke survivor compliance to taking medication: Study

12 Aug 2010

Simple morning walk to school could reduce stress reactivity in children: Study

A simple morning walk to school could reduce stress reactivity in children during the school day, curbing increases in heart rate and blood pressure that can lead to cardiovascular disease later in life, according to a new University at Buffalo study.

11 Aug 2010

Entelos receives patent for PhysioLab virtual patient technology

Entelos, Inc. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,774,182, entitled "Apparatus and Method for Validating a Computer Model." This patent was issued to Entelos for its invention of an innovative computer-implemented method for validating multiple virtual patients within a computer model. The PhysioLab virtual patient technology allows Entelos life scientists and engineers to more rapidly evaluate the safety and efficacy of new therapeutics in a diverse population of patients. This predictive power is integrated into our PhysioLab platforms, which have been used by our pharmaceutical and consumer product customers for over a decade to dramatically reduce the risk, time, and cost of product development.

11 Aug 2010

Study shows physicians reluctant to use finasteride for prostate cancer

Despite the dramatic results of the Prostate Cancer Prevention Trial (PCPT), which showed a significant reduction in prostate cancer among those taking finasteride, physicians have not increased its use, according to a study published in the September issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

11 Aug 2010

Vanguard Management, Go Healthy announce consulting, management and distribution agreement

Vanguard Management Corp (a business unit of Vanguard Minerals Corp) announced that the company has signed a comprehensive consulting, management and distribution agreement with Go Healthy, Inc, a marketer of innovative nutrition products, namely Cholesterade.

10 Aug 2010

Older Americans suffer from full-blown depression: Report

Maureen Duffy's memories of her grandmother are cloudy. Not because of time, but by a condition that cast a shadow over the woman Duffy had visited as a child.

10 Aug 2010

Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that its MARINE trial, a Phase 3 clinical trial of AMR101, has completed patient enrollment and randomization into the treatment phase of this trial. The Company indicated that top line results from this trial are expected early in 2011, towards the early part of the range of guidance provided previously.

10 Aug 2010

Isis second-quarter pro forma net operating loss increases to $15.5 million

Isis Pharmaceuticals, Inc. today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009.

9 Aug 2010

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Nature describing the discovery and validation of the role of the gene Sort1 in the development of cardiovascular disease, including myocardial infarction (MI). This work was done with collaborators at University of Pennsylvania (UPenn) School of Medicine, Massachusetts General Hospital (MGH), and the Broad Institute. The collaborative effort combined genome-wide association studies (GWAS) and RNAi technology to identify and validate novel genes as targets for new therapies for heart disease.

6 Aug 2010

Eliminating depression, diabetes can reduce levels of dementia: Study

Eliminating diabetes and depression, as well as increasing education and fruit and vegetable consumption, are likely to have the biggest impact on reducing levels of dementia in the coming years, should no effective treatment be found, concludes a study published on bmj.com today.These findings suggest priorities for future public health interventions.While the exact cause of dementia is still unknown, several modifiable risk factors have already been identified. These include vascular risk factors (heart disease, stroke, high blood pressure, obesity, diabetes, and high cholesterol), a history of depression, diet, alcohol consumption, and education level.

6 Aug 2010

Diabetes Self-Management Training helps to prevent complications in pre diabetes patients

Citing research that demonstrates the cost savings and health benefits of providing Diabetes Self-Management Training (DSMT) to patients with pre-diabetes, the American Association of Diabetes Educators today called on private insurers and Medicare to include education as a covered benefit for this population.

5 Aug 2010

Genzyme, Isis announce results of two mipomersen phase 3 studies

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy. In the study of patients with severe hypercholesterolemia, mipomersen reduced LDL-C, the primary endpoint, by 36 percent compared with a 13 percent increase for placebo.

5 Aug 2010

Sigma-Aldrich, NHLBI and BU collaborate in atherosclerotic cardiovascular disease research

Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.

5 Aug 2010

SORT1 pathway holds promise as new target for therapeutic intervention for LDL cholesterol reduction

The true power of genomic research lies in its ability to help scientists understand biological processes, particularly those that - when altered - can lead to disease. This power is demonstrated dramatically in a pair of papers published today in the journal Nature. In the first, a global team of researchers describes 95 different variations across the genome that contribute in different degrees to alterations in blood cholesterol and triglyceride levels in multiple human populations. In the second report, close examination of just one of these common variants not only reveals the involvement of an unexpected genetic pathway in lipid metabolism but also provides a blueprint for using genomic findings to unravel biological connections between lipid levels and coronary heart disease.

5 Aug 2010

Detection of Alzheimer's before symptoms occur

Research is on to detect the dreaded Alzheimer's disease even before any symptoms occur. In a newly proposed diagnostic criteria developed by experts from the National Institute on Aging and the Alzheimer's Association three stages of the disease viz. pre-clinical Alzheimer's, mild cognitive impairment and Alzheimer's dementia are described.

4 Aug 2010

Scientists identify 95 gene loci that influence lipoprotein metabolism in humans

In a large-scale international study in which Helmholtz Zentrum München participated, scientists have identified 95 gene loci which influence lipoprotein metabolism in humans. Viewed from a long-term perspective, these findings open up new lines of research in the prevention and treatment of coronary artery disease. It is the first genome-wide association study of this kind to be published in the prestigious journal Nature.

4 Aug 2010

Cholesterol News and Research

Further Reading

Statin drugs can neutralise heart disease dangers of fatty food: Study

FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients

Fast food outlets can provide statin drugs to help customers neutralise heart disease: Researchers

25% of stroke patients stop taking prevention medication within 3 months

Modifiable factors associated with stroke survivor compliance to taking medication: Study

Simple morning walk to school could reduce stress reactivity in children: Study

Entelos receives patent for PhysioLab virtual patient technology

Study shows physicians reluctant to use finasteride for prostate cancer

Vanguard Management, Go Healthy announce consulting, management and distribution agreement

Older Americans suffer from full-blown depression: Report

Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial

Isis second-quarter pro forma net operating loss increases to $15.5 million

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Eliminating depression, diabetes can reduce levels of dementia: Study

Diabetes Self-Management Training helps to prevent complications in pre diabetes patients

Genzyme, Isis announce results of two mipomersen phase 3 studies

Sigma-Aldrich, NHLBI and BU collaborate in atherosclerotic cardiovascular disease research

SORT1 pathway holds promise as new target for therapeutic intervention for LDL cholesterol reduction

Detection of Alzheimer's before symptoms occur

Scientists identify 95 gene loci that influence lipoprotein metabolism in humans

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News